— Led U.S. and International Commercial Operations at Amgen Inc.–
BOSTON, April 13, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced the appointment on April 11, 2018 of Rolf K. Hoffman, a global biopharmaceutical industry executive with more than three decades of experience, to the Company’s board of directors. At the same time, long-time director Richard Lim stepped down from the board effective April 11, 2018.